Testing effectiveness (Phase 2)Study completedNCT01185158
What this trial is testing
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
Who this might be right for
Head and Neck Cancer
University of Chicago 46